+24.5%
ALAB vs MRNA
+945.0%
-920.5%
-53.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.4% | +13.1% | -17.5% | -4.6% |
| 7D | -24.9% | +20.6% | -45.5% | -25.1% |
| 30D | -38.4% | +27.1% | -65.5% | -38.5% |
| 3M | -38.3% | +353.4% | -391.6% | -40.9% |
| 6M | +10.9% | +446.3% | -435.3% | -0.4% |
| YTD | +34.2% | +776.2% | -742.0% | -0.4% |
| 1Y | +24.5% | +987.9% | -963.4% | -11.4% |
| All | +24.5% | +945.0% | -920.5% | -11.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling